PHATHOM PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $15.67 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $15.69, a 171.92% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $5.77, a 25.64% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $7.76, a 7.40% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $8.38, a 45.44% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $5.53, a 32.48% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $8.19, a 4.10% decline from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $8.54, a 41.59% decline from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $14.62, a 60.64% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.67 10-Q · filed 2026-07-30 | |||
| 2026-03-31 | $15.69 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $5.53 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $5.15 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | $5.11 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $5.77 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $8.19 10-K · filed 2025-03-06 | |||
| 2024-09-30 | $8.11 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $8.07 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $7.76 10-Q/A · filed 2024-06-14 | |||
| 2023-12-31 | $8.54 10-K/A · filed 2024-06-14 | |||
| 2023-09-30 | $8.78 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $8.68 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $8.38 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $14.62 10-K/A · filed 2024-06-14 | |||
| 2022-09-30 | $14.75 10-Q/A · filed 2022-11-09 | |||
| 2022-06-30 | $14.76 10-Q · filed 2022-08-02 | |||
| 2022-03-31 | $15.36 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $37.14 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $38.61 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $38.77 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $39.06 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $33.55 10-K · filed 2021-03-30 | |||
| 2020-09-30 | $32.14 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $32.34 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $34.39 10-Q · filed 2020-05-12 | |||
| 2019-12-31 | $9.10 10-K · filed 2020-03-19 | |||
| 2019-09-30 | $9.10 10-Q · filed 2019-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |